Cargando…
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of ce...
Autores principales: | Gençler, Bilgen, Gönül, Müzeyyen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794559/ https://www.ncbi.nlm.nih.gov/pubmed/27042173 http://dx.doi.org/10.1155/2016/5361569 |
Ejemplares similares
-
Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective
por: Fratta, Elisabetta, et al.
Publicado: (2023) -
Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018) -
A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
por: Tian, Yangzi, et al.
Publicado: (2020) -
Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients
por: Zhou, Sarah, et al.
Publicado: (2021) -
Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)